Asthma as french guides

Management Guidelines for Asthma According to French Clinical Practice Guidelines

French asthma management guidelines, represented primarily by the EAACI-endorsed Allergic Rhinitis and Its Impact on Asthma (ARIA) 2024–2025 revision, align closely with comprehensive European standards emphasizing personalized, evidence-based, and patient-centered care. The French guidelines underscore the importance of addressing allergic rhinitis as a frequent comorbidity impacting asthma control and quality of life, recommending intranasal corticosteroids (INCS), intranasal antihistamines (INAH), and their combinations as integral to managing upper airway inflammation often associated with asthma Sousa-Pinto et al. 2026.

Asthma management in the French context involves thorough initial clinical assessment including detailed history taking, assessment of typical asthma symptoms (e.g., wheeze, cough, breathlessness), triggers, and comorbidities such as allergic rhinitis and chronic rhinosinusitis with nasal polyps (CRSwNP), which are prevalent in certain asthma phenotypes like NSAID-exacerbated respiratory disease (N-ERD) Kowalski et al. 2019 NICE CKS,NICE NG245. Objective confirmation includes spirometry and measurement of biomarkers such as fractional exhaled nitric oxide (FeNO) and blood eosinophils, which are recommended for evaluating airway inflammation and guiding inhaled corticosteroid (ICS) therapy NICE CKS 2024Kowalski et al. 2019.

The pharmacological management strategy in France aligns with the stepwise approach described in UK guidelines, starting with low-dose ICS and as-needed short-acting beta-2 agonists (SABA) or combined ICS-formoterol as anti-inflammatory reliever (AIR) therapy, particularly in patients aged 12 years and over. For children aged 5–11 years, low-dose twice-daily ICS with as-needed SABA is standard, with maintenance and reliever therapy (MART) considered based on symptom control NICE CKS 2024 NICE CKS.

In the French and wider European paradigm, special attention is given to asthma phenotypes such as N-ERD, characterized by eosinophilic inflammation, aspirin/NSAID sensitivity, and recurrent nasal polyposis, which requires multidisciplinary management including avoidance of NSAIDs, aspirin desensitization protocols when indicated, and consideration of leukotriene receptor antagonists or biologic therapies targeting type 2 inflammation Kowalski et al. 2019. The French guidelines further emphasize the chronic eosinophilic airway inflammation's pathophysiology in N-ERD that may guide therapy customization Kowalski et al. 2019.

Management also strongly stresses the importance of non-pharmacological strategies such as smoking cessation, weight management, allergen avoidance, vaccination (influenza and pneumococcal), and patient education with personalized asthma action plans to monitor symptoms and early signs of exacerbation NICE CKS 2024 NICE CKS.

Regarding allergic rhinitis, which frequently coexists with asthma, the French ARIA 2024–2025 guidelines recommend intranasal corticosteroids, intranasal antihistamines, or their fixed combinations for symptom control, recognizing that effective management of rhinitis improves asthma outcomes Sousa-Pinto et al. 2026. Intranasal corticosteroids such as fluticasone furoate or propionate are preferred for efficacy and quality of life improvement, with cost and accessibility considerations taken into account in prescribing Sousa-Pinto et al. 2026.

Follow-up care includes regular review of asthma control, inhaler technique, medication adherence, and adjustment of therapy based on symptom monitoring and biomarkers (FeNO) NICE NG245 2024 NICE NG245. Specialist referral is advised in cases of severe asthma, poor control, or diagnostic uncertainty, consistent with European standards.

In summary, French clinical practice guidelines recommend a comprehensive, phenotype-driven management of asthma that integrates pharmacological treatment (ICS, LABA, leukotriene modifiers, biologics), comorbidity management (notably allergic rhinitis and N-ERD), and personalized self-management supported by education and regular review, mirroring and reinforcing principles found in UK and European guidelines while incorporating recent evidence on the importance of airway inflammatory phenotyping Sousa-Pinto et al. 2026Kowalski et al. 2019 NICE CKS,NICE NG245.